Journal
GENE THERAPY
Volume 17, Issue 1, Pages 141-146Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/gt.2009.119
Keywords
retrograde transport; primate; adeno-associated virus (AAV); motor neurons; amyotrophic lateral sclerosis (ALS); spinal muscular atrophy (SMA)
Categories
Funding
- Bruno and Ilse Frick Foundation
- Axion Research Foundation
Ask authors/readers for more resources
Retrograde transport of viral vectors in the rodent spinal cord provides a powerful means to administer a therapeutic transgene from the innervated musculature. With the aim of scaling up this approach to non-human primates, we have injected recombinant adeno-associated vectors (rAAV) serotype 6 expressing enhanced green fluorescent protein (eGFP) into the gastrocnemius muscle of African green monkeys to determine whether this results in efficient transgene delivery to lumbar motor neurons. Cells expressing eGFP were observed across more than 1 cm of the spinal cord 4 weeks after intramuscular injection, reaching more than half of motor neurons in some cross-sections. Furthermore, quantitative PCR on the spinal cord tissue confirmed that eGFP expression within motor neurons was due to bona fide retrograde transport of the vector genome from the muscle. Although infiltrations of macrophages and lymphocytes were observed in the rAAV2/6-injected muscle, there was no detectable immune response within the transduced region of the spinal cord. These findings imply that retrograde delivery of rAAV serotype 6 in a primate species constitutes a non-invasive and robust approach to transduce motor neurons, a crucial target cell population in neurodegenerative disorders, such as amyotrophic lateral sclerosis and spinal muscular atrophy. Gene Therapy (2010) 17, 141-146; doi: 10.1038/gt.2009.119; published online 3 September 2009
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available